Efficient nanoparticle mediated sustained RNA interference in human primary endothelial cells

Nanotechnology

Volumn 22, Issue 44, 2011, Pages

  Mukerjee, Anindita ^a   Shankardas, Jwalitha ^a   Ranjan, Amalendu P ^a   Vishwanatha, Jamboor K ^a  

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT TREATMENT; AGE-RELATED MACULAR DEGENERATION; ANGIOGENESIS; ANNEXINS; CANCER CELLS; DIABETIC RETINOPATHY; DOWN-REGULATION; GENE SILENCING; HUMAN CANCER CELLS; LIPOFECTAMINE; MICROVASCULAR ENDOTHELIAL CELLS; PATHOPHYSIOLOGICAL; PLGA NANOPARTICLES; POLY(D ,L-LACTIDE-CO-GLYCOLIDE); RETINOPATHY OF PREMATURITY; RNA INTERFERENCE; SHORT HAIRPIN RNA (SHRNA); SMALL INTERFERING RNA (SIRNA); TRANSFECTION EFFICIENCY; VASCULAR FUNCTIONS; VIABLE CELLS;

ANTIBIOTICS; CELL CULTURE; DISEASES; DRUG THERAPY; EYE PROTECTION; GENE THERAPY; GENETIC ENGINEERING; LIPOSOMES; NANOPARTICLES; OPHTHALMOLOGY; ORGANIC POLYMERS; RNA; TOXICITY;

ENDOTHELIAL CELLS;

LACTIC ACID; LIPID; LIPOCORTIN 2; LIPOFECTAMINE; NANOPARTICLE; POLYGLYCOLIC ACID; POLYLACTIC ACID POLYGLYCOLIC ACID COPOLYMER; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; SMALL INTERFERING RNA;

ANGIOGENESIS; ARTICLE; CANCER INVASION; CELL DEATH; CHEMISTRY; DOWN REGULATION; ENDOCYTOSIS; ENDOTHELIUM CELL; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; METABOLISM; METHODOLOGY; NANOTECHNOLOGY; PARTICLE SIZE; RNA INTERFERENCE; TUMOR CELL LINE; ULTRASTRUCTURE; WESTERN BLOTTING;

ANNEXIN A2; BLOTTING, WESTERN; CELL DEATH; CELL LINE, TUMOR; DOWN-REGULATION; ENDOCYTOSIS; ENDOTHELIAL CELLS; GENE EXPRESSION; HUMANS; LACTIC ACID; LIPIDS; NANOPARTICLES; NANOTECHNOLOGY; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PHYSIOLOGIC; PARTICLE SIZE; POLYGLYCOLIC ACID; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 80054884173     PISSN: 09574484     EISSN: 13616528     Source Type: Journal    
DOI: 10.1088/0957-4484/22/44/445101     Document Type: Article

References (49)

1. Kovala A T, Harvey K A, McGlynn P, Boguslawski G, Garcia J G and English D 2000 High-efficiency transient transfection of endothelial cells for functional analysis FASEB J. 14 2486-94
2. Folkman J 1995 Angiogenesis in cancer, vascular, rheumatoid and other disease Nature Med. 1 27-31
3. Risau W 1997 Mechanisms of angiogenesis Nature 386 671-4 (Pubitemid 27193480)
4. Zetter B R 1998 Angiogenesis and tumor metastasis Annu. Rev. Med. 49 407-24 (Pubitemid 28197463)
5. Huang C, Li M, Chen C and Yao Q 2008 Small interfering RNA therapy in cancer: mechanism, potential targets, and clinical applications Expert Opin. Ther. Targets 12 637-45 (Pubitemid 351699481)
6. Singh S K 2008 RNA interference and its therapeutic potential against HIV infection Expert Opin. Biol. Ther. 8 449-61 (Pubitemid 351570409)
7. Cun D, Foged C, Yang M, Frokjaer S and Nielsen H M 2010 Preparation and characterization of poly(DL-lactide-co-glycolide) nanoparticles for siRNA delivery Int. J. Pharm. 390 70-5
8. Xie F Y, Woodle M C and Lu P Y 2006 Harnessing in vivo siRNA delivery for drug discovery and therapeutic development Drug Discov. Today 11 67-73 (Pubitemid 43227854)
9. Tanner F C, Carr D P, Nabel G J and Nabel E G 1997 Transfection of human endothelial cells Cardiovasc. Res. 35 522-8 (Pubitemid 27469414)
10. Niebauer J, Dulak J, Chan J R, Tsao P S and Cooke J P 1999 Gene transfer of nitric oxide synthase: effects on endothelial biology J. Am. Coll. Cardiol. 34 1201-7 (Pubitemid 29500561)
11. Merrick A F, Shewring L D, Sawyer G J, Gustafsson K T and Fabre J W 1996 Comparison of adenovirus gene transfer to vascular endothelial cells in cell culture, organ culture, and in vivo Transplantation 62 1085-9 (Pubitemid 26376657)
12. Wrighton C J, Hofer-Warbinek R, Moll T, Eytner R, Bach F H and de Martin R 1996 Inhibition of endothelial cell activation by adenovirus-mediated expression of I kappa B alpha, an inhibitor of the transcription factor NF-kappa B J. Exp. Med. 183 1013-22
13. Cartiera M S, Johnson K M, Rajendran V, Caplan M J and Saltzman W M 2009 The uptake and intracellular fate of PLGA nanoparticles in epithelial cells Biomaterials 30 2790-8
14. des Rieux A, Fievez V, Garinot M, Schneider Y J and Preat V 2006 Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach J. Control. Release 116 1-27 (Pubitemid 44792295)
15. Prego C, Garcia M, Torres D and Alonso M J 2005 Transmucosal macromolecular drug delivery J. Control. Release 101 151-62 (Pubitemid 39600979)
16. Hans M L and Lowman A M 2002 Biodegradable nanoparticles for drug delivery and targeting Curr. Opin. Solid State Mater. Sci. 6 319-27 (Pubitemid 36238389)
17. Soppimath K S, Aminabhavi T M, Kulkarni A R and Rudzinski W E 2001 Biodegradable polymeric nanoparticles as drug delivery devices J. Control. Release 70 1-20 (Pubitemid 32144788)
18. Luo D and Saltzman W M 2000 Synthetic DNA delivery systems Nature Biotechnol. 18 33-7 (Pubitemid 30041168)
19. Panyam J and Labhasetwar V 2003 Biodegradable nanoparticles for drug and gene delivery to cells and tissue Adv. Drug Deliv. Rev. 55 329-47 (Pubitemid 36297053)
20. Mukerjee A and Vishwanatha J K 2009 Formulation, characterization and evaluation of curcumin-loaded PLGA nanospheres for cancer therapy Anticancer Res. 29 3867-75
21. Gary D J, Puri N and Won Y Y 2007 Polymer-based siRNA delivery: perspectives on the fundamental and phenomenological distinctions from polymer-based DNA delivery J. Control. Release 121 64-73 (Pubitemid 47126065)
22. Ling Q et al 2004 Annexin II regulates fibrin homeostasis and neoangiogenesis in vivo J. Clin. Invest. 113 38-48 (Pubitemid 38541630)
23. Valapala M, Thamake S I and Vishwanatha J K 2011 A competitive hexapeptide inhibitor of annexin A2 prevents hypoxia-induced angiogenic events J. Cell. Sci. 124 1453-64
24. Balch C and Dedman J R 1997 Annexins II and V inhibit cell migration Exp. Cell Res. 237 259-63 (Pubitemid 28027920)
25. Chiang Y, Rizzino A, Sibenaller Z A, Wold M S and Vishwanatha J K 1999 Specific down-regulation of annexin II expression in human cells interferes with cell proliferation Mol. Cell. Biochem. 199 139-47 (Pubitemid 29476152)
26. Liu J, Rothermund C A, Ayala-Sanmartin J and Vishwanatha J K 2003 Nuclear annexin II negatively regulates growth of LNCaP cells and substitution of ser 11 and 25 to glu prevents nucleo-cytoplasmic shuttling of annexin II BMC Biochem. 4 10
27. Vishwanatha J K, Chiang Y, Kumble K D, Hollingsworth M A and Pour P M 1993 Enhanced expression of annexin II in human pancreatic carcinoma cells and primary pancreatic cancers Carcinogenesis 14 2575-9 (Pubitemid 24016599)
28. Sharma M C and Sharma M 2007 The role of annexin II in angiogenesis and tumor progression: a potential therapeutic target Curr. Pharm. Des. 13 3568-75 (Pubitemid 350238927)
29. Browning A C, Gray T and Amoaku W M 2005 Isolation, culture, and characterisation of human macular inner choroidal microvascular endothelial cells Br. J. Ophthalmol. 89 1343-7 (Pubitemid 41638878)
30. Rao D D, Vorhies J S, Senzer N and Nemunaitis J 2009 siRNA vs. shRNA: similarities and differences Adv. Drug Deliv. Rev. 61 746-59
31. Hombreiro Perez M et al 2000 The preparation and evaluation of poly(epsilon-caprolactone) microparticles containing both a lipophilic and a hydrophilic drug J. Control. Release 65 429-38 (Pubitemid 30122944)
32. Hoffart V, Lamprecht A, Maincent P, Lecompte T, Vigneron C and Ubrich N 2006 Oral bioavailability of a low molecular weight heparin using a polymeric delivery system J. Control. Release 113 38-42 (Pubitemid 43818166)
33. Budhian A, Siegel S J and Winey K I 2008 Controlling the in vitro release profiles for a system of haloperidol-loaded PLGA nanoparticles Int. J. Pharm. 346 151-9 (Pubitemid 350101995)
34. Sahoo S K, Panyam J, Prabha S and Labhasetwar V 2002 Residual polyvinyl alcohol associated with poly (D,L-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake J. Control. Release 82 105-14 (Pubitemid 34775052)
35. Misra S, Hascall V C, De Giovanni C, Markwald R R and Ghatak S 2009 Delivery of CD44 shRNA/nanoparticles within cancer cells: perturbation of hyaluronan/CD44v6 interactions and reduction in adenoma growth in Apc Min/ + MICE J. Biol. Chem. 284 12432-46
36. Yu W, Liu C, Ye J, Zou W, Zhang N and Xu W 2009 Novel cationic SLN containing a synthesized single-tailed lipid as a modifier for gene delivery Nanotechnology 20 215102
37. Ofek P, Fischer W, Calderon M, Haag R and Satchi-Fainaro R 2010 In vivo delivery of small interfering RNA to tumors and their vasculature by novel dendritic nanocarriers FASEB J. 24 3122-34
38. Rejman J, Oberle V, Zuhorn I S and Hoekstra D 2004 Size-dependent internalization of particles via the pathways of clathrin-and caveolae-mediated endocytosis Biochem. J. 377 159-69 (Pubitemid 38114443)
39. Win K Y and Feng S S 2005 Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs Biomaterials 26 2713-22
40. He C, Hu Y, Yin L, Tang C and Yin C 2010 Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles Biomaterials 31 3657-66
41. Ranjan A P, Zeglam K, Mukerjee A, Thamake S and Vishwanatha J K 2011 A sustained release formulation of chitosan modified PLCL: poloxamer blend nanoparticles loaded with optical agent for animal imaging Nanotechnology 22 295104
42. Sharma M, Ownbey R T and Sharma M C 2010 Breast cancer cell surface annexin II induces cell migration and neoangiogenesis via tPA dependent plasmin generation Exp. Mol. Pathol. 88 278-86
43. Cesarman G M, Guevara C A and Hajjar K A 1994 An endothelial cell receptor for plasminogen/tissue plasminogen activator (t-PA). II. Annexin II-mediated enhancement of t-PA-dependent plasminogen activation J. Biol. Chem. 269 21198-203
44. Hajjar K A, Jacovina A T and Chacko J 1994 An endothelial cell receptor for plasminogen/tissue plasminogen activator. I. Identity with annexin II J. Biol. Chem. 269 21191-7
45. Brownstein C et al 2004 Annexin II mediates plasminogen-dependent matrix invasion by human monocytes: enhanced expression by macrophages Blood 103 317-24 (Pubitemid 38029955)
46. Tarui T, Majumdar M, Miles L A, Ruf W and Takada Y 2002 Plasmin-induced migration of endothelial cells. A potential target for the anti-angiogenic action of angiostatin J. Biol. Chem. 277 33564-70
47. Liang C C, Park A Y and Guan J L 2007 In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro Nature Prot. 2 329-33 (Pubitemid 47040047)
48. Zhao S, Huang L, Wu J, Zhang Y, Pan D and Liu X 2009 Vascular endothelial growth factor upregulates expression of annexin A2 in vitro and in a mouse model of ischemic retinopathy Mol. Vis. 15 1231-42
49. Kim N H, Jung H J, Shibasaki F and Kwon H J 2010 NBBA, a synthetic small molecule, inhibits TNF-alpha-induced angiogenesis by suppressing the NF-kappaB signaling pathway Biochem. Biophys. Res. Commun. 391 1500-5